Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.
Who: Cosette Pharmaceuticals/Mayne Pharma Group Ltd.
What: Cosette is acquiring struggling Mayne to strengthen its position in women’s health and dermatology in a take-private transaction.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
The French drugmaker is expanding its neurology activities with the $470m deal.
Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.
Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
